肥胖成人抗菌药物给药综合指导
本文为叙述性综述,检索PubMed、Scopus和Cochrane Library,基于2336篇文献中的121篇,为34种抗菌药物制定肥胖成人给药建议。其中11种无需调整剂量,其余23种提供肥胖特异性给药指导;对时间依赖性抗菌药物(如β-内酰胺类)建议考虑延长输注,并强调治疗药物监测的重要性。
要点
- 肥胖成人中11种抗菌药物无需剂量调整,23种需肥胖特异性给药指导。
- 时间依赖性抗菌药物(如β-内酰胺类)在肥胖患者中应考虑延长输注以达到PD目标。
- 治疗药物监测在肥胖患者中日益重要,有助于优化给药。
核心结论
- 肥胖成人中多数抗菌药物需肥胖特异性给药指导,仅部分无需调整剂量。
- 延长输注等替代策略可提高时间依赖性抗菌药物的PD目标达成率。
- 治疗药物监测对确保肥胖患者抗菌药物剂量优化具有重要价值。
研究设计与样本
- 叙述性综述,检索PubMed、Scopus和Cochrane Library,最终基于121篇文献制定给药建议。
主要发现
- 从2336篇文献中纳入121篇,为34种抗菌药物制定给药建议。
- 34种抗菌药物中11种无需剂量调整,23种提供肥胖特异性给药指导。
- 已发表的临床和PK证据多为小样本回顾性研究,结果异质性大甚至矛盾。
关键数值与推荐
- 对时间依赖性抗菌药物(如β-内酰胺类),肥胖患者应考虑延长输注以可靠达到PD目标。
- 治疗药物监测在肥胖及其他人群中日益重要,用于优化给药。
临床怎么用
- 临床应参考本文为34种抗菌药物制定的肥胖成人给药建议,其中23种需按肥胖特异性指导调整。
- 对β-内酰胺类等时间依赖性抗菌药物,肥胖患者可优先考虑延长输注策略。
- 应积极开展治疗药物监测以个体化调整肥胖患者的抗菌药物剂量。
局限性
- 已发表的临床和PK证据多为小样本回顾性研究,结果异质性大且部分矛盾。
- 需进一步研究以解决已发表抗菌药物PK结果的差异,确立肥胖成人最佳给药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Physiologic alterations seen in obesity commonly impact the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics and may result in suboptimal dosing in this expanding but understudied population. Much of the published clinical and PK evidence to date consists of small patient populations and are retrospective with, not infrequently, heterogeneous results that in some cases are contradictory. In the last 10 years, additional antimicrobial PK/PD and clinical data encompassing prolonged infusion strategies and examination of critically ill populations have emerged to inform antimicrobial dosing in obesity. In this narrative review, we critically review literature on dosing, PK, and possible dosing strategies in obese adults. We searched PubMed, Scopus, and the Cochrane Library using Medical Subject Headings including anti-infectives, specific antimicrobial names, obese, pharmacokinetics, and others. We reviewed articles, cross-referenced select cited references, and when applicable, referenced drug databases and package inserts to develop dosing recommendations. We provide an overall critical review of the available data regarding PK and dosing issues including dosing recommendations in both critically ill and noncritically ill patients with significant obesity. We developed dosing recommendations for 34 antimicrobials based on 121 articles of the 2336 identified by the search strategy. Although 11 of these do not appear to require dose adjustment, obesity-specific dosing guidance is provided for the remaining 23 antimicrobials. Additional studies are needed to better understand and resolve discrepant published results regarding the PK of antibiotics to establish optimal dosing strategies in obese adults. Alternative dosing strategies, such as extended infusions, should be considered for time-dependent antibiotics (e.g., β-lactams) in obese patients to achieve PD targets reliably. Therapeutic drug monitoring across the spectrum of antimicrobials is of increasing importance in this and other populations to ensure optimized dosing.
引用
- Meng L, Mui E, Holubar MK, et al. Comprehensive Guidance for Antibiotic Dosing in Obese Adults. Pharmacotherapy. 2017. PMID: 28869666. doi:10.1002/phar.2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。